SYFOVRE (Pegcetacoplan) Patent Expiration, LOE Window & CMS Spending

SYFOVRE (Pegcetacoplan) by Apellis: FDA Orange Book core substance LOE 2038-12-14, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,256 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApellis
FDA Application & PathwayN217171 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-12-14
Last Listed Patent or Exclusivity Date2038-12-14
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,256 intro WAC)